RS58242B1 - Režim doziranja za inhibitore janus kinaze (jak) - Google Patents

Režim doziranja za inhibitore janus kinaze (jak)

Info

Publication number
RS58242B1
RS58242B1 RS20190051A RSP20190051A RS58242B1 RS 58242 B1 RS58242 B1 RS 58242B1 RS 20190051 A RS20190051 A RS 20190051A RS P20190051 A RSP20190051 A RS P20190051A RS 58242 B1 RS58242 B1 RS 58242B1
Authority
RS
Serbia
Prior art keywords
jak
inhibitors
dosing regimen
janus kinase
janus
Prior art date
Application number
RS20190051A
Other languages
English (en)
Inventor
Andrea J Gonzales
Sallie B Cosgrove
Phyllis B Malpas
Michael Rolf Stegemann
Wendy Turner Collard
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58242(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of RS58242B1 publication Critical patent/RS58242B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
RS20190051A 2012-07-20 2013-07-18 Režim doziranja za inhibitore janus kinaze (jak) RS58242B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors
EP13742573.2A EP2874630B1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
RS58242B1 true RS58242B1 (sr) 2019-03-29

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190051A RS58242B1 (sr) 2012-07-20 2013-07-18 Režim doziranja za inhibitore janus kinaze (jak)

Country Status (24)

Country Link
US (1) US9522151B2 (sr)
EP (1) EP2874630B1 (sr)
JP (2) JP6022063B2 (sr)
KR (2) KR20150028299A (sr)
CN (2) CN108354938A (sr)
AU (1) AU2013292547B2 (sr)
BR (1) BR112015000808A2 (sr)
CA (1) CA2878867C (sr)
CY (1) CY1121436T1 (sr)
DK (1) DK2874630T3 (sr)
ES (1) ES2707627T3 (sr)
HK (2) HK1209314A1 (sr)
HR (1) HRP20182088T1 (sr)
HU (1) HUE042771T2 (sr)
IN (1) IN2015DN00370A (sr)
LT (1) LT2874630T (sr)
MX (1) MX360857B (sr)
NZ (1) NZ703152A (sr)
PL (1) PL2874630T3 (sr)
PT (1) PT2874630T (sr)
RS (1) RS58242B1 (sr)
SI (1) SI2874630T1 (sr)
WO (1) WO2014015107A1 (sr)
ZA (1) ZA201500134B (sr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008664A0 (en) 2013-02-22 2015-08-31 Pfizer Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
AU2016340167B2 (en) 2015-10-16 2021-06-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2017143014A1 (en) * 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
PL3915989T3 (pl) * 2019-01-30 2023-12-11 Felicamed Biotechnology Co., Ltd Inhibitor jak i sposób jego otrzymywania
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
AU2021401834A1 (en) 2020-12-18 2023-07-06 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4666762B2 (ja) * 1998-06-19 2011-04-06 ファイザー・プロダクツ・インク ピロロ[2.3−d]ピリミジン化合物
BRPI0917459B1 (pt) * 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide

Also Published As

Publication number Publication date
HK1252083A1 (zh) 2019-05-17
AU2013292547B2 (en) 2017-05-04
NZ703152A (en) 2016-03-31
ES2707627T3 (es) 2019-04-04
HRP20182088T1 (hr) 2019-02-08
US9522151B2 (en) 2016-12-20
PL2874630T3 (pl) 2019-04-30
HUE042771T2 (hu) 2019-07-29
WO2014015107A1 (en) 2014-01-23
CN104470525A (zh) 2015-03-25
MX360857B (es) 2018-11-20
KR20150028299A (ko) 2015-03-13
DK2874630T3 (en) 2019-01-28
CN108354938A (zh) 2018-08-03
CA2878867C (en) 2018-01-09
KR20170034949A (ko) 2017-03-29
JP2017019816A (ja) 2017-01-26
JP6022063B2 (ja) 2016-11-09
EP2874630A1 (en) 2015-05-27
CY1121436T1 (el) 2020-05-29
IN2015DN00370A (sr) 2015-06-12
MX2015000871A (es) 2015-05-07
LT2874630T (lt) 2019-02-11
BR112015000808A2 (pt) 2017-06-27
AU2013292547A1 (en) 2015-01-22
CA2878867A1 (en) 2014-01-23
US20150126535A1 (en) 2015-05-07
SI2874630T1 (sl) 2019-04-30
PT2874630T (pt) 2019-01-31
JP2015522620A (ja) 2015-08-06
HK1209314A1 (en) 2016-04-01
EP2874630B1 (en) 2018-12-05
ZA201500134B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
HRP20182088T1 (hr) Režim doziranja za inhibitore janus kinaze (jak)
HK1254429A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
HK1212683A1 (zh) 多個激酶途徑抑制劑
HK1222647A1 (zh) 激酶抑制劑
EP2758051A4 (en) CYANOMETHYLPYRAZOLCARBOXAMIDES AS JANUS KINASEINHIBITORS
HUE048834T2 (hu) Kináz inhibitorok
HK1211574A1 (en) Serine threonine kinase inhibitors
HK1209277A1 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6-
PL2634185T3 (pl) Inhibitory kinazy TYK2
IL229028A0 (en) Kinase inhibitors
HK1213252A1 (zh) 雙環二氫吡啶酮激酶抑制劑
HK1199873A1 (en) Kinase inhibitors
EP2895167A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
HK1213181A1 (zh) 雙環氧雜內酰胺激酶抑制劑